Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Monday . The stock had previously closed at $50.51, but opened at $48.2450. Zealand Pharma A/S shares last traded at $48.24, with a volume of 435 shares.

Analyst Upgrades and Downgrades

ZLDPF has been the topic of a number of recent research reports. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Finally, Zacks Research lowered shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a market capitalization of $3.71 billion, a P/E ratio of 8.59 and a beta of 0.88. The stock’s fifty day simple moving average is $46.59 and its 200-day simple moving average is $48.47. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.